Panacea Biotec [PANACEABIO] vs 3B Blackbio [3BBLACKBIO] Detailed Stock Comparison
Panacea Biotec
NSE
Loading...
3B Blackbio
BSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Panacea Biotec wins in 7 metrics, 3B Blackbio wins in 11 metrics, with 0 ties. 3B Blackbio appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Panacea Biotec | 3B Blackbio | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 217.10 | 25.06 | 3B Blackbio |
| Price-to-Book Ratio | 2.98 | 4.79 | Panacea Biotec |
| Debt-to-Equity Ratio | 2.67 | 0.11 | 3B Blackbio |
| PEG Ratio | -1.73 | 1.91 | Panacea Biotec |
| EV/EBITDA | -182.28 | 23.83 | Panacea Biotec |
| Profit Margin (TTM) | 1.88% | 49.51% | 3B Blackbio |
| Operating Margin (TTM) | -5.74% | 51.98% | 3B Blackbio |
| EBITDA Margin (TTM) | N/A | 51.98% | N/A |
| Return on Equity | -1.01% | 17.58% | 3B Blackbio |
| Return on Assets (TTM) | -0.65% | 16.11% | 3B Blackbio |
| Free Cash Flow (TTM) | $-776.80M | $424.53M | 3B Blackbio |
| 1-Year Return | 79.88% | 2.74% | Panacea Biotec |
| Price-to-Sales Ratio (TTM) | 4.10 | 12.42 | Panacea Biotec |
| Enterprise Value | $24.12B | $12.16B | Panacea Biotec |
| EV/Revenue Ratio | 3.95 | 12.25 | Panacea Biotec |
| Gross Profit Margin (TTM) | 53.68% | 75.00% | 3B Blackbio |
| Revenue per Share (TTM) | $100 | $116 | 3B Blackbio |
| Earnings per Share (Diluted) | $1.88 | $57.31 | 3B Blackbio |
| Beta (Stock Volatility) | 0.34 | 0.28 | 3B Blackbio |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Panacea Biotec vs 3B Blackbio Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Panacea Biotec | -2.16% | -1.20% | -3.47% | -25.64% | 25.69% | -8.21% |
| 3B Blackbio | 1.64% | -11.51% | -1.70% | -25.19% | -20.50% | -27.08% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Panacea Biotec | 79.88% | 188.45% | 155.14% | 208.41% | 111.26% | 51.88% |
| 3B Blackbio | 2.74% | 80.63% | 80.63% | 80.63% | 80.63% | 80.63% |
Performance & Financial Health Analysis: Panacea Biotec vs 3B Blackbio
| Metric | PANACEABIO | 3BBLACKBIO |
|---|---|---|
| Market Information | ||
| Market Cap | ₹25.00B | ₹12.33B |
| Market Cap Category | Small cap | Small cap |
| 10 Day Avg. Volume | 235,549 | 11,965 |
| 90 Day Avg. Volume | 190,641 | 8,132 |
| Last Close | ₹394.70 | ₹1,436.75 |
| 52 Week Range | ₹200.05 - ₹581.90 | ₹1,253.80 - ₹2,350.00 |
| % from 52W High | -32.17% | -38.86% |
| All-Time High | ₹581.90 (Apr 28, 2025) | ₹2,350.00 (Dec 09, 2024) |
| % from All-Time High | -32.17% | -38.86% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.44% | 0.14% |
| Quarterly Earnings Growth | 0.44% | 0.13% |
| Financial Health | ||
| Profit Margin (TTM) | 0.02% | 0.50% |
| Operating Margin (TTM) | -0.06% | 0.52% |
| Return on Equity (TTM) | -0.01% | 0.18% |
| Debt to Equity (MRQ) | 2.67 | 0.11 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | ₹136.92 | ₹299.81 |
| Cash per Share (MRQ) | ₹17.95 | ₹14.62 |
| Operating Cash Flow (TTM) | ₹-1,547,900,000 | ₹619.97M |
| Levered Free Cash Flow (TTM) | ₹-83,700,000 | ₹476.52M |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | ₹0.00 | N/A |
Valuation & Enterprise Metrics Analysis: Panacea Biotec vs 3B Blackbio
| Metric | PANACEABIO | 3BBLACKBIO |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 217.10 | 25.06 |
| Forward P/E | N/A | N/A |
| PEG Ratio | -1.73 | 1.91 |
| Price to Sales (TTM) | 4.10 | 12.42 |
| Price to Book (MRQ) | 2.98 | 4.79 |
| Market Capitalization | ||
| Market Capitalization | ₹25.00B | ₹12.33B |
| Enterprise Value | ₹24.12B | ₹12.16B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.95 | 12.25 |
| Enterprise to EBITDA | -182.28 | 23.83 |
| Risk & Other Metrics | ||
| Beta | 0.34 | 0.28 |
| Book Value per Share (MRQ) | ₹136.92 | ₹299.81 |
Financial Statements Comparison: Panacea Biotec vs 3B Blackbio
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | PANACEABIO | 3BBLACKBIO |
|---|---|---|
| Revenue/Sales | ₹1.33B | ₹222.35M |
| Cost of Goods Sold | ₹520.80M | ₹55.60M |
| Gross Profit | ₹804.50M | ₹166.75M |
| Research & Development | N/A | N/A |
| Operating Income (EBIT) | ₹-353.00M | ₹115.57M |
| EBITDA | ₹-182.90M | ₹161.51M |
| Pre-Tax Income | ₹-400,000 | ₹158.64M |
| Income Tax | ₹19.50M | ₹32.19M |
| Net Income (Profit) | ₹-19.90M | ₹126.45M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | PANACEABIO | 3BBLACKBIO |
|---|---|---|
| Cash & Equivalents | ₹821.30M | ₹124.73M |
| Total Current Assets | ₹5.45B | ₹1.32B |
| Total Current Liabilities | ₹3.67B | ₹185.88M |
| Long-Term Debt | ₹222.10M | ₹3.07M |
| Total Shareholders Equity | ₹8.31B | ₹2.71B |
| Retained Earnings | N/A | N/A |
| Property, Plant & Equipment | ₹5.43B | ₹72.19M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | PANACEABIO | 3BBLACKBIO |
|---|---|---|
| Operating Cash Flow | N/A | N/A |
| Capital Expenditures | N/A | N/A |
| Free Cash Flow | N/A | N/A |
| Debt Repayment | N/A | N/A |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | PANACEABIO | 3BBLACKBIO |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 235,549 | 11,965 |
| Average Daily Volume (90 Day) | 190,641 | 8,132 |
| Shares Outstanding | 61.25M | 8.58M |
| Float Shares | 15.44M | 2.62M |
| % Held by Insiders | 0.73% | 0.65% |
| % Held by Institutions | 0.00% | 0.02% |
Dividend Analysis & Yield Comparison: Panacea Biotec vs 3B Blackbio
| Metric | PANACEABIO | 3BBLACKBIO |
|---|---|---|
| Last 12-Month Dividend | ₹0.00 | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | ₹0.00 | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | ₹0.00 | N/A |
| Ex-Dividend Date | N/A | N/A |